drugset
drugset / Trial / NCT06323655

Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

NCT06323655 ↗

Phase 1 Completed 48 enrolled Vanda Pharmaceuticals
RandomizedCrossoverQuadruple-blindBasic science

Summary

The aim of this study is to investigate next-day residual effects of tasimelteon compared with placebo and active control in healthy subjects.

Timeline

Start
2018-07-19
Primary completion
2018-08-28
Completion
2018-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule 20 mg Oral

Indications

No indication recorded.